Incyte (NAS:INCY) Net Income

: $876 Mil (TTM As of Sep. 2022)

View and export this data going back to 1993. Start your Free Trial

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Incyte's Net Income for the three months ended in Sep. 2022 was $113 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2022 was $876 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Incyte's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $0.50.

Incyte Net Income Historical Data

The historical data trend for Incyte's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Income

-313.14

109.49

446.91

-295.70

948.58

Incyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Income																181.74	563.85	37.99	161.43	112.78

Incyte Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Incyte's Net Income for the fiscal year that ended in Dec. 2021 is calculated as

	Net Income		(A: Dec. 2021 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	570.444	+	378.137	+	0	+	1.1368683772162E-13
=	949

Incyte's Net Income for the quarter that ended in Sep. 2022 is calculated as

	Net Income		(Q: Sep. 2022 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	148.588	+	-35.813	+	0	+	1.4210854715202E-14
=	113

Net Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $876 Mil.

Incyte (NAS:INCY) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Incyte's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2022 is calculated as

Earnings per Share (Diluted) (Q: Sep. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(112.775	-	0)	/	224.175
	=	0.50

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Incyte Net Income Related Terms

Thank you for viewing the detailed overview of Incyte's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (NAS:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

INCY:Mexico 0J9P:UK ICY:Germany ICY:Germany I1NC34:Brazil INCY:Austria

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Tray Thomas	officer: Principal Accounting Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W	director	5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A	director	3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund	director
Morrissey Michael James	officer: EVP, Head of Tech. Operations	IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana	officer: EVP & Chief Financial Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E	officer: EVP & General Counsel	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A	director	C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul	officer: VP, Finance & Prin Acc Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J	director	C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques	director	925 PAGE MILL ROAD PALO ALTO CA 94304